

Piyusha P Pagare

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4716700/publications.pdf>

Version: 2024-02-01

23
papers

287
citations

1039880

9
h-index

940416

16
g-index

23
all docs

23
docs citations

23
times ranked

383
citing authors

#	ARTICLE	IF	CITATIONS
1	Uracil-coumarin based hybrid molecules as potent anti-cancer and anti-bacterial agents. <i>Journal of Saudi Chemical Society</i> , 2020, 24, 251-266.	2.4	45
2	Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease. <i>Molecular Pharmaceutics</i> , 2017, 14, 3499-3511.	2.3	39
3	A Chemical Biology Approach to the Chaperome in Cancer—HSP90 and Beyond. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a034116.	2.3	32
4	Crystal structure of carbonmonoxy sickle hemoglobin in R-state conformation. <i>Journal of Structural Biology</i> , 2016, 194, 446-450.	1.3	30
5	Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2530-2538.	1.4	26
6	Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation. <i>Acta Crystallographica Section D: Structural Biology</i> , 2018, 74, 956-964.	1.1	15
7	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. <i>Scientific Reports</i> , 2020, 10, 20277.	1.6	14
8	Drug discovery efforts toward inhibitors of canonical Wnt/ β -catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010–2020). <i>Drug Discovery Today</i> , 2022, 27, 1115-1127.	3.2	13
9	Rational approaches for the design of various GABA modulators and their clinical progression. <i>Molecular Diversity</i> , 2021, 25, 551-601.	2.1	9
10	Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 115-130.	2.4	9
11	Understanding the role of glucose regulated protein 170 (GRP170) as a nucleotide exchange factor through molecular simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 85, 160-170.	1.3	7
12	Exploration of Structure–Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14724-14739.	2.9	7
13	Structural modification of azolylacryloyl derivatives yields a novel class of covalent modifiers of hemoglobin as potential antisickling agents. <i>MedChemComm</i> , 2019, 10, 1900-1906.	3.5	6
14	Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5095-5112.	2.9	6
15	Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT _{2B} receptor antagonist scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127511.	1.0	5
16	Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers. <i>Bioorganic Chemistry</i> , 2022, 120, 105641.	2.0	5
17	Understanding molecular interactions between scavenger receptor A and its natural product inhibitors through molecular modeling studies. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 77, 189-199.	1.3	4
18	Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease. <i>Pharmaceutics</i> , 2021, 13, 1148.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Exploration of naphthoquinone analogs in targeting the TCF-DNA interaction to inhibit the Wnt/ β^2 -catenin signaling pathway. <i>Bioorganic Chemistry</i> , 2022, 124, 105812.	2.0	4
20	Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 72-76.	1.0	3
21	Development of structure-based pharmacophore to target the β^2 -catenin-TCF protein-protein interaction. <i>Medicinal Chemistry Research</i> , 2021, 30, 429-439.	1.1	3
22	PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation. <i>Blood</i> , 2019, 134, 73-73.	0.6	1
23	Calpain-1 Contributes to Pain and Organ Damage in Sickle Cell Disease. <i>Blood</i> , 2019, 134, 76-76.	0.6	0